GLP-1 & Cardiovascular Protection: SELECT Trial −20% MACE in Non-Diabetic Obesity, LEADER −13% in T2D, and the Mechanisms Behind Plaque Stabilization

Why GLP-1 Cardiovascular Trials Changed Cardiology

Before 2016, the FDA required all new diabetes drugs to demonstrate cardiovascular safety — a response to the rosiglitazone controversy that suggested some glucose-lowering agents might increase CV risk despite improving HbA1c. These mandated cardiovascular outcomes trials (CVOTs) were designed to prove non-inferiority, not superiority. What actually happened redefined expectations for the entire drug class.

LEADER (liraglutide, 2016), SUSTAIN-6 (semaglutide injectable, 2016), and PIONEER 6 (oral semaglutide, 2019) all showed not just non-inferiority but superiority — meaning GLP-1 agonists actively reduced cardiovascular events vs. placebo in patients already on optimal background therapy. This was unexpected. The glucose hypothesis — that lower blood sugar = fewer cardiovascular events — had already been challenged by ACCORD and ADVANCE. GLP-1 agonists were doing something beyond glycemic control.

SELECT (2023) delivered the definitive proof: in 17,604 patients with established cardiovascular disease but WITHOUT diabetes, semaglutide 2.4mg subcutaneous weekly reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% vs. placebo over a median follow-up of 33 months. There was no glucose-lowering effect to explain this — the cardioprotection had to come from other mechanisms.

The LEADER Trial: The Blueprint for GLP-1 Cardioprotection in T2D

LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) enrolled 9,340 T2D patients with high cardiovascular risk (established CVD or age ≥60 with ≥1 CV risk factor). Randomized to liraglutide 1.8mg/day vs. placebo, added to standard care, for a median of 3.8 years.

Primary endpoint (3-point MACE: CV death, non-fatal MI, non-fatal stroke):

• Liraglutide: 13.0% of patients experienced primary endpoint event
• Placebo: 14.9% of patients experienced primary endpoint event
• Hazard ratio 0.87 (95% CI 0.78–0.97), p=0.01 for superiority — 13% relative risk reduction

The component driving the benefit was primarily cardiovascular death (−22% relative risk reduction) rather than non-fatal MI or stroke individually. This pattern — where CV mortality benefit exceeds non-fatal event reduction — suggests liraglutide may be stabilizing vulnerable plaques (preventing fatal rupture events) rather than just reducing event frequency.

Exploratory analyses showed the benefit emerged within the first 12 months of treatment — faster than would be expected from weight loss or HbA1c improvement alone (both of which take longer to translate into CV event reduction). This early divergence of the survival curves supports a direct vascular mechanism operating independently of metabolic improvements.

SELECT (2023): Cardioprotection Decoupled from Glucose

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) published in NEJM 2023 is the landmark paper that forced a re-evaluation of mechanism. Design: 17,604 patients, age ≥45, BMI ≥27, established CVD, but no history of diabetes (confirmed by HbA1c <6.5% at baseline). Randomized to semaglutide 2.4mg weekly vs. placebo for a planned 5-year duration (median follow-up 33 months at interim analysis).

Primary endpoint (3-point MACE):

• Semaglutide: 6.5% event rate (annualized)
• Placebo: 8.0% event rate (annualized)
• HR 0.80 (95% CI 0.72–0.90), p<0.001 — 20% relative risk reduction

The weight loss in the semaglutide group was approximately −9.4% of body weight. But multiple lines of evidence suggest this doesn't fully explain the CV benefit:

1. The cardiovascular risk reduction emerged before significant weight loss was achieved (event curves diverged at ~3 months when weight loss was only ~2–3%)
2. Historical data on non-pharmacological weight loss of similar magnitude (bariatric surgery excepted) does not show 20% MACE reductions in this timeframe
3. Mechanistic studies show direct GLP-1R-mediated effects on vascular endothelium, inflammatory cells, and cardiac muscle that are weight-independent

Direct Vascular Mechanisms: Beyond Weight and Glucose

Endothelial Protection

GLP-1 receptors are expressed on vascular endothelial cells throughout the coronary and systemic vasculature. GLP-1R activation in endothelium promotes:

• eNOS phosphorylation (endothelial nitric oxide synthase activation) — increasing NO production, causing vasodilation and reducing platelet aggregation
• Reduced ICAM-1 and VCAM-1 expression — adhesion molecules that recruit monocytes to endothelial surfaces, a key early step in atherosclerotic plaque formation
• Reduced endothelial NF-κB activation — suppressing inflammatory gene expression in vessel walls

Macrophage Foam Cell Formation Inhibition

Atherosclerotic plaques form when LDL penetrates the endothelium, becomes oxidized, and is taken up by monocyte-derived macrophages via scavenger receptors. These lipid-laden macrophages ("foam cells") form the lipid core of plaques. GLP-1R agonists reduce oxidized LDL uptake by macrophages — directly inhibiting foam cell formation — through mechanisms involving cAMP-PKA signaling that downregulates scavenger receptor expression (particularly SR-A and CD36).

Plaque Stabilization

The majority of fatal cardiovascular events result not from slowly progressive stenosis but from plaque rupture — acute fracture of a vulnerable fibrous cap, exposing thrombogenic plaque contents to blood flow. Vulnerable plaques have thin fibrous caps, large necrotic lipid cores, and dense macrophage infiltration. GLP-1 agonists appear to promote plaque stabilization by:

• Reducing macrophage-mediated inflammation within plaques (macrophages produce MMPs that degrade fibrous cap collagen)
• Increasing collagen synthesis in vascular smooth muscle cells (thickening the fibrous cap)
• Reducing oxidative stress within plaques (less lipid peroxidation = more stable lesion)

This mechanism explains why the cardiovascular mortality benefit in LEADER appeared within 12 months — you don't need years to stabilize a vulnerable plaque, you just need to reduce the pro-inflammatory state that was destabilizing it.

Blood Pressure and Heart Rate Effects

GLP-1 agonists consistently reduce systolic blood pressure by 2–5 mmHg in clinical trials. The mechanism is partially natriuretic (promoting sodium and water excretion via renal GLP-1R), partially vasodilatory (eNOS-mediated), and partially related to weight loss. Even small blood pressure reductions meaningfully impact MACE risk (every 5 mmHg SBP reduction corresponds to approximately 10% lower CV risk in population data).

An offsetting effect: GLP-1 agonists slightly increase heart rate by approximately 2–4 bpm. The cardiac mechanism is sympathomimetic — GLP-1R activation on sinoatrial node cells. The net cardiovascular effect is still clearly beneficial despite this tachycardic tendency, but it explains why GLP-1 agonists are used cautiously in patients with resting tachycardia.

Recommended Resources